Metastatic Behavior of Breast Cancer Subtypes
Top Cited Papers
- 10 July 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (20), 3271-3277
- https://doi.org/10.1200/jco.2009.25.9820
Abstract
Purpose Prognostic and predictive factors are well established in early-stage breast cancer, but less is known about which metastatic sites will be affected. Methods Patients with early-stage breast cancer diagnosed between 1986 and 1992 with archival tissue were included. Subtypes were defined as luminal A, luminal B, luminal/human epidermal growth factor receptor 2 (HER2), HER2 enriched, basal-like, and triple negative (TN) nonbasal. Distant sites were classified as brain, liver, lung, bone, distant nodal, pleural/peritoneal, and other. Cumulative incidence curves were estimated for each site according to competing risks methods. Association between the site of relapse and subtype was assessed in multivariate models using logistic regression. Results Median follow-up time among 3,726 eligible patients was 14.8 years. Median durations of survival with distant metastasis were 2.2 (luminal A), 1.6 (luminal B), 1.3 (luminal/HER2), 0.7 (HER2 enriched), and 0.5 years (basal-like; P < .001). Bone was the most common metastatic site in all subtypes except basal-like tumors. In multivariate analysis, compared with luminal A tumors, luminal/HER2 and HER2-enriched tumors were associated with a significantly higher rate of brain, liver, and lung metastases. Basal-like tumors had a higher rate of brain, lung, and distant nodal metastases but a significantly lower rate of liver and bone metastases. TN nonbasal tumors demonstrated a similar pattern but were not associated with fewer liver metastases. Conclusion Breast cancer subtypes are associated with distinct patterns of metastatic spread with notable differences in survival after relapse.Keywords
This publication has 49 references indexed in Scilit:
- Molecular Basis of MetastasisNew England Journal of Medicine, 2008
- Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast CancersJournal of Clinical Oncology, 2008
- Lung metastasis genes couple breast tumor size and metastatic spreadProceedings of the National Academy of Sciences of the United States of America, 2007
- Mediators of vascular remodelling co-opted for sequential steps in lung metastasisNature, 2007
- Is cancer a disease of self-seeding?Nature Medicine, 2006
- Genes Associated With Breast Cancer Metastatic to BoneJournal of Clinical Oncology, 2006
- Genes that mediate breast cancer metastasis to lungNature, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- A multigenic program mediating breast cancer metastasis to boneCancer Cell, 2003
- Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patientsCancer, 1985